The mystery of why some individuals accumulate Alzheimer's disease pathology yet maintain cognitive function may hinge on how their brain's immune cells respond at a critical juncture. This finding could reshape approaches to preventing dementia in aging populations by targeting immune resilience rather than just clearing protein plaques. Researchers identified distinct microglial cell transitions occurring precisely when amyloid-β and tau proteins reach pathological thresholds in the human brain. These immune cells exhibited markedly different activation patterns between individuals who developed dementia versus those who remained cognitively intact despite similar protein burden. The study revealed specific molecular signatures that distinguish protective microglial responses from those leading to neurodegeneration. This represents a significant advance in understanding Alzheimer's heterogeneity at the cellular level. Previous research has established that microglia play dual roles in neurodegeneration—both clearing harmful proteins and potentially causing inflammation that damages neurons. However, this work provides the first detailed mapping of how these cells behave at the critical inflection point where pathology either progresses to dementia or remains clinically silent. The implications for therapeutic intervention are substantial, suggesting that enhancing microglial resilience pathways could prevent cognitive decline even when protein aggregates are present. This challenges the dominant amyloid hypothesis by demonstrating that pathology accumulation alone doesn't determine clinical outcomes. While the study provides crucial mechanistic insights, translating these findings into treatments will require identifying druggable targets within the resilience pathways and validating interventions that can shift microglial responses toward protective phenotypes.